3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Non-Hodgkin
1
Interventions
Rituximab
70
Cyclophosphamide
46
fludarabine
21
fludarabine phosphate
20
Mycophenolic Acid
20
Etoposide
18
Whole-Body Irradiation
17
Filgrastim
15
Radiotherapy
14
Antilymphocyte Serum
14
Tacrolimus
13
Melphalan
13
Gemcitabine
13
Cyclosporine
13
Busulfan
13
Methotrexate
12
Lenalidomide
12
Bortezomib
12
Bendamustine Hydrochloride
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
Cytarabine
10
Doxorubicin
8
Dexamethasone
8
venetoclax
7
thymoglobulin
7
pembrolizumab
7
Thiotepa
7
Methylprednisolone
7
Granulocyte Colony-Stimulating Factor
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, Non-Hodgkin
×
loncastuximab tesirine
×
Clear all
NCT05144009
2025-01-30
LOTIS-9
ADC Therapeutics S.A.
Phase 2
Terminated
41 enrolled
19 charts